Faron Pharmaceuticals OY (FARN) NPV
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
Faron Pharmaceuticals CFO stands down
15 April 2024 09:36
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals revealed on Monday that chief financial officer James O'Brien would be leaving the group to "pursue another career...
-
Faron Pharmaceuticals taps Juho Jalkanen for CEO
8 April 2024 09:17
(Sharecast News) - Biopharmaceutical company Faron Pharmaceuticals named Dr Juho Jalkanen as its next chief executive officer on Monday.
-
Faron shares jump on encouraging trial data
18 March 2024 14:14
(Sharecast News) - Faron Pharmaceuticals announced further encouraging data from the first phase of its 'BEXMAB' trial on Monday, targeting higher-risk (HR) myelodysplastic syndrome (MDS) patients...
-
Faron Pharmaceuticals reports year of clinical progress
13 March 2024 11:52
(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals reported a year of strong progress on Wednesday, with significant overall response rates seen in both previously...
-
Faron Pharmaceuticals shores up cash with EUR 3.2m convertible loans
4 March 2024 10:40
(Sharecast News) - Faron Pharmaceuticals announced on Monday that it has successfully secured binding commitments for convertible loans totalling €3.2m from a select group of existing shareholders.
-
Faron launches second phase of leukaemia treatment trial
9 January 2024 12:36
(Sharecast News) - Faron Pharmaceuticals has initiated phase two of the BEXMAB trial, it announced on Tuesday, marking a significant milestone in its cancer treatment development programme.
-
Faron unveils promising antibody study results
11 December 2023 13:22
(Sharecast News) - Faron Pharmaceuticals unveiled promising phase one data from its BEXMAB study in myeloid malignancies during the 65th American Society of Hematology (ASH) annual meeting, it announced on...
-
Faron publishes cancer immunotherapy study findings
7 December 2023 11:01
(Sharecast News) - Faron Pharmaceuticals announced the publication of the comprehensive findings from the groundbreaking phase one and two 'MATINS' trial of bexmarilimab on Thursday - its humanised...
-
Faron reveals details of next stage of bexmarilimab study
6 November 2023 10:31
(Sharecast News) - Faron Pharmaceuticals announced on Monday that, following guidance from the US Food and Drug Administration (FDA), the initial indication for phase two advancement in the study...
-
Faron Pharmaceuticals upbeat on latest data in blood cancer trials
11 October 2023 14:53
(Sharecast News) - Faron Pharmaceuticals announced encouraging updated data from its ongoing phase one and two 'BEXMAB' study into relapsed or refractory (r/r) acute myeloid leukaemia (AML) and...
-
Faron Pharmaceuticals names interim chief medical officer
21 September 2023 14:45
(Sharecast News) - Cancer immunotherapy-focussed biopharmaceutical firm Faron Pharmaceuticals named Dr Birge Berns as its interim chief medical officer on Thursday, with the transition becoming effective on...
-
Faron Pharmaceuticals names James O'Brien as CFO
29 March 2023 09:38
(Sharecast News) - Drug discovery and development company Faron Pharmaceuticals has tapped James O'Brien to take over as its new chief financial officer.
Company announcements Announcements
-
Appointment of Chief Financial Officer
15 April 2024 07:00
Faron Pharmaceuticals Oy (DI)
-
Approval of Warrant Terms and Conditions
8 April 2024 07:10
Faron Pharmaceuticals Oy (DI)
-
Decisions of the Board of Directors
8 April 2024 07:05
Faron Pharmaceuticals Oy (DI)
-
Appointment of Chief Executive Officer
8 April 2024 07:00
Faron Pharmaceuticals Oy (DI)
-
Results of the Annual General Meeting
5 April 2024 12:00
Faron Pharmaceuticals Oy (DI)
-
Announcement of Placing
4 April 2024 07:00
Faron Pharmaceuticals Oy (DI)
-
Issue of Warrants to IPF Funding Update
28 March 2024 07:00
Faron Pharmaceuticals Oy (DI)
-
Faron´s Annual Report 2023
26 March 2024 10:00
Faron Pharmaceuticals Oy (DI)
-
Additional Positive Data from Phase 1 of BEXMAB
18 March 2024 07:00
Faron Pharmaceuticals Oy (DI)
-
Notice of Annual General Meeting 2024
13 March 2024 14:00
Faron Pharmaceuticals Oy (DI)
-
Financial Statement January 1 to December 31 2023
13 March 2024 07:00
Faron Pharmaceuticals Oy (DI)
-
Binding commitments for convertible loans
4 March 2024 07:00
Faron Pharmaceuticals Oy (DI)
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.